PET Imaging with 18F-FDG for Cervical Cancer

This trial tests whether a special imaging technique can better identify cancerous lymph nodes in the pelvis of women with certain types of cervical or endometrial cancer. By using a radioactive substance called 18F-Fluorodeoxyglucose (18F-FDG) during a PET/CT or PET/MRI scan, researchers aim to see cancer more clearly before surgery. Women diagnosed with stage IB1 cervical cancer or certain high-grade endometrial cancers who are planning for surgery might be suitable candidates. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative imaging technique.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that 18F-Fluorodeoxyglucose (18F-FDG) is often used in PET scans to help detect cancer in the body. Studies have found it useful for determining the stage of cervical cancer and planning treatment. This helps doctors understand the extent of cancer spread and decide on the best treatment plan.

Regarding safety, 18F-FDG is generally well-tolerated. Although it is a radioactive substance, only small amounts are used during scans. No specific evidence from these studies indicates negative side effects when injected into the cervix. However, since this study is in its early phase, it primarily focuses on safety, and any risks are closely monitored.

Researchers are excited about using 18F-Fluorodeoxyglucose (18F-FDG) in combination with PET/CT and PET/MRI imaging for cervical cancer because it offers a unique approach to detecting cancerous tissues. Unlike traditional imaging methods, which might not clearly distinguish between healthy and cancerous cells, 18F-FDG highlights cancer cells by targeting their higher glucose uptake, making them stand out more vividly during scans. This targeted approach could potentially lead to more precise staging and treatment planning, allowing doctors to tailor interventions more effectively. Additionally, using advanced imaging techniques like PET/MRI can provide more detailed information about the tumor's structure and activity, which could improve surgical outcomes and overall patient management.

This trial will evaluate the effectiveness of 18F-FDG PET/CT and PET/MRI imaging for cervical cancer. Studies have shown that 18F-FDG PET/CT scans effectively detect cervical cancer, especially in identifying cancer in the lymph nodes near the cervix and uterus. One study found these scans to be 88.7% accurate in predicting primary cervical cancer, with a high ability to both detect cancer and confirm its absence. PET/MRI scans also demonstrate high accuracy and surpass MRI alone in assessing cancer spread. Both types of scans help predict patient response to treatment, making them valuable tools in managing cervical cancer.⁴⁶⁷⁸⁹